Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Sumitomo Dainippon Logs Double-Digit Growth on Diabetes Meds: April-December
Sumitomo Dainippon Pharma netted 10%-plus sales growth in the first three quarters of FY2020, buoyed by its diabetes franchise in Japan and its flagship antipsychotic Latuda (lurasidone) in North America. In April-December, the Osaka drug maker posted group sales of…
To read the full story
Related Article
- Sumitomo Ups FY2025 Forecast on North America-Driven Profit Growth
November 4, 2025
- Sumitomo Pharma Rejoins PhRMA amid US Tariff Concerns, Posts H1 Forecasts
August 1, 2025
- Sumitomo Pharma Logs 1st Operating Profit in 3 Years in FY2024
May 14, 2025
- Sumitomo Ups FY2024 Earnings Outlook, Now Expects Black Ink
February 3, 2025
- Sumitomo’s FY2024 1H Results Meet Initial Plan amid Restructuring
October 31, 2024
- Sumitomo Sales Surge 18% in April-September on 3 Key Brands
October 31, 2024
- As Latuda Sales Evaporate, Sumitomo Shakes Up Top Brass for Turnaround
May 15, 2024
- Sumitomo to Cut Med- to Long-Term Guidance amid Tepid Uptake of New Drivers
February 1, 2024
- Sumitomo Eyes Return to Core Operating Profit in FY2024, Pruning Roivant Shares
November 1, 2023
- Sumitomo’s Group Sales Halve in Q1 as Latuda LOE in US Takes Toll
August 1, 2023
- Sumitomo Incurs 77 Billion Yen Operating Loss in FY2022 on Kynmobi Impairment Charge
May 16, 2023
- Sumitomo Suffers 18.5 Billion Yen Net Loss in April-December on Kynmobi Woes
February 1, 2023
- Sumitomo Posts 7.3 Billion Yen Net Loss in H1 on Kynmobi Write-Down
November 1, 2022
- Sumitomo’s Q1 Sales Zoom 22% on FX, Cancer Drug License Fee
August 1, 2022
- Sumitomo’s FY2021 Sales Up 8.5% on Otsuka Pact, North America/China Growth; Chairman Tada to Retire
May 16, 2022
- Sumitomo Dainippon’s 9-Month Profit Sinks 33.5% on US Promotions, Other Factors
February 1, 2022
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Sumitomo Dainippon’s Q1 Sales Skid 2.0% on Lower Latuda Revenue
July 30, 2021
- Sumitomo Dainippon Sees 6.9% Sales Growth on Latuda, Diabetes Med; Name Change Announced
May 13, 2021
- Sumitomo Dainippon’s Half-Year Sales Up 13.4% on Latuda Growth
October 29, 2020
- Sumitomo Dainippon’s Q1 Sales Up 13.9% on Equa/EquMet Contribution
August 3, 2020
BUSINESS
- Astellas Tops 2 Trillion Yen in Sales, Gears Up for Post-Xtandi Growth
April 28, 2026
- Astellas Taps Sanofi Japan Chief Iwaya as Strategy Officer
April 28, 2026
- Teikoku, Curedisc Ink Japan Deal for Disc Herniation Drug
April 28, 2026
- FRONTEO, Science Tokyo Roll Out AI Drug Discovery Hub
April 28, 2026
- Kyorin to Transfer Generics Unit to Daito-Led JV
April 28, 2026
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…